Logo image of LUNG

PULMONX CORP (LUNG) Stock Fundamental Analysis

NASDAQ:LUNG - Nasdaq - US7458481014 - Common Stock - Currency: USD

8.96  +0.18 (+2.05%)

After market: 8.76 -0.2 (-2.23%)

Fundamental Rating

3

LUNG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of LUNG is average, but there are quite some concerns on its profitability. LUNG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

LUNG had negative earnings in the past year.
In the past year LUNG has reported a negative cash flow from operations.
In the past 5 years LUNG always reported negative net income.
In the past 5 years LUNG always reported negative operating cash flow.
LUNG Yearly Net Income VS EBIT VS OCF VS FCFLUNG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.11%, LUNG is in line with its industry, outperforming 42.55% of the companies in the same industry.
LUNG has a Return On Equity (-60.80%) which is in line with its industry peers.
Industry RankSector Rank
ROA -34.11%
ROE -60.8%
ROIC N/A
ROA(3y)-28.44%
ROA(5y)-27.25%
ROE(3y)-38.29%
ROE(5y)-48.83%
ROIC(3y)N/A
ROIC(5y)N/A
LUNG Yearly ROA, ROE, ROICLUNG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

1.3 Margins

The Gross Margin of LUNG (74.16%) is better than 84.57% of its industry peers.
LUNG's Gross Margin has improved in the last couple of years.
LUNG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.49%
GM growth 5Y3.76%
LUNG Yearly Profit, Operating, Gross MarginsLUNG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

5

2. Health

2.1 Basic Checks

LUNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
LUNG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LUNG Yearly Shares OutstandingLUNG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M
LUNG Yearly Total Debt VS Total AssetsLUNG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -0.73, we must say that LUNG is in the distress zone and has some risk of bankruptcy.
LUNG has a Altman-Z score (-0.73) which is in line with its industry peers.
A Debt/Equity ratio of 0.40 indicates that LUNG is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.40, LUNG is in line with its industry, outperforming 43.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z -0.73
ROIC/WACCN/A
WACC9.16%
LUNG Yearly LT Debt VS Equity VS FCFLUNG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

LUNG has a Current Ratio of 7.70. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
LUNG has a better Current ratio (7.70) than 88.83% of its industry peers.
LUNG has a Quick Ratio of 6.77. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 6.77, LUNG belongs to the top of the industry, outperforming 89.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.7
Quick Ratio 6.77
LUNG Yearly Current Assets VS Current LiabilitesLUNG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

LUNG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.50%, which is quite good.
EPS 1Y (TTM)12.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%23.3%

3.2 Future

The Earnings Per Share is expected to grow by 11.69% on average over the next years. This is quite good.
LUNG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.81% yearly.
EPS Next Y-16.35%
EPS Next 2Y0.37%
EPS Next 3Y8.75%
EPS Next 5Y11.69%
Revenue Next Year18.72%
Revenue Next 2Y19.33%
Revenue Next 3Y20.02%
Revenue Next 5Y17.81%

3.3 Evolution

LUNG Yearly Revenue VS EstimatesLUNG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M
LUNG Yearly EPS VS EstimatesLUNG Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LUNG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LUNG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUNG Price Earnings VS Forward Price EarningsLUNG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUNG Per share dataLUNG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.37%
EPS Next 3Y8.75%

More info and screens

0

5. Dividend

5.1 Amount

LUNG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULMONX CORP

NASDAQ:LUNG (2/21/2025, 8:00:00 PM)

After market: 8.76 -0.2 (-2.23%)

8.96

+0.18 (+2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)04-29 2025-04-29/amc
Inst Owners93.99%
Inst Owner Change1.35%
Ins Owners4.93%
Ins Owner Change-1.66%
Market Cap353.83M
Analysts80
Price Target11.82 (31.92%)
Short Float %3.24%
Short Ratio5.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.3%
Min EPS beat(2)19.29%
Max EPS beat(2)21.31%
EPS beat(4)4
Avg EPS beat(4)19.36%
Min EPS beat(4)13.32%
Max EPS beat(4)23.51%
EPS beat(8)8
Avg EPS beat(8)13.56%
EPS beat(12)11
Avg EPS beat(12)9.17%
EPS beat(16)15
Avg EPS beat(16)10.21%
Revenue beat(2)1
Avg Revenue beat(2)-0.14%
Min Revenue beat(2)-1.48%
Max Revenue beat(2)1.2%
Revenue beat(4)3
Avg Revenue beat(4)1.61%
Min Revenue beat(4)-1.48%
Max Revenue beat(4)3.43%
Revenue beat(8)7
Avg Revenue beat(8)4.03%
Revenue beat(12)8
Avg Revenue beat(12)2.43%
Revenue beat(16)11
Avg Revenue beat(16)3.9%
PT rev (1m)0%
PT rev (3m)-17.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.46
P/FCF N/A
P/OCF N/A
P/B 3.77
P/tB 3.86
EV/EBITDA N/A
EPS(TTM)-1.4
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS2.01
BVpS2.38
TBVpS2.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.11%
ROE -60.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.16%
FCFM N/A
ROA(3y)-28.44%
ROA(5y)-27.25%
ROE(3y)-38.29%
ROE(5y)-48.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.49%
GM growth 5Y3.76%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 103.09%
Cap/Sales 1.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.7
Quick Ratio 6.77
Altman-Z -0.73
F-Score4
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)187.13%
Cap/Depr(5y)189.11%
Cap/Sales(3y)3.74%
Cap/Sales(5y)3.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.33%
EPS Next Y-16.35%
EPS Next 2Y0.37%
EPS Next 3Y8.75%
EPS Next 5Y11.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%23.3%
Revenue Next Year18.72%
Revenue Next 2Y19.33%
Revenue Next 3Y20.02%
Revenue Next 5Y17.81%
EBIT growth 1Y9.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.24%
EBIT Next 3Y15.39%
EBIT Next 5Y7.15%
FCF growth 1Y27.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.69%
OCF growth 3YN/A
OCF growth 5YN/A